G

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Enterprise Technology Lead Senior Manager

Full-TimeUpdated on 10/23/2026
$153.9k - $199.2k+ Discretionary annual bonus + Discretionary stock-based long-term incentives
Expert
Bachelor's, Master's
El Segundo, CA, USA
HybridHybrid-eligible onsite workplace; occasional travel to Kite/Gilead locations may be required.
IT OperationsEnterprise Applications
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A Master's degree and 8 or more years of relevant information technology experience, or a Bachelor's degree and 12 or more years of relevant information technology experience.
  • At least 10 years of experience supporting enterprise resource planning platforms, including Oracle E-Business Suite, SAP S/4HANA, SAP ECC, and related applications.
  • At least 5 years of experience leading digital operations, technical delivery, production support, or managed service teams in a complex global environment.
  • Ability to build trusted relationships with senior business and technology stakeholders, understand operational priorities, and influence technology decisions as a strategic advisor.
  • Strong business acumen and ability to connect technology strategy, architecture, and delivery decisions to operational outcomes, patient impact, risk reduction, and measurable business value.
  • Strong understanding of end-to-end supply chain, manufacturing, logistics, finance, order-to-cash, procure-to-pay, inventory, warehouse management, and related life sciences business processes.
  • Hands-on experience with migration, integration, and application delivery across platforms such as Oracle EBS, SAP, Salesforce, Veeva, Sitecore, and related downstream systems.
  • Strong technical knowledge of middleware platforms, APIs, web services, event-driven integrations, integration patterns, data transformation, reconciliation, data quality, and master data management.
  • Experience with digital operations and support governance, including incident and problem management, ITIL service management, monitoring, operational reporting, root cause analysis, corrective actions, change and release management, environment management, and risk mitigation.
  • Ability to lead solution design reviews, establish technical standards, oversee SDLC delivery, manage third-party vendors and global delivery partners, and drive outcomes in a matrixed organization.
  • Strong systems thinking, analytical problem-solving, communication, facilitation, stakeholder management, influencing, project and portfolio management, ownership, accountability, and operational rigor.
  • Ability to balance strategic planning with hands-on operational execution, manage competing priorities in a fast-paced environment, and communicate complex technology considerations, risks, options, and recommendations clearly to technical, operational, and executive audiences.
  • Ability to perform in ambiguous environments and under pressure; engage and manage stakeholders at all levels; listen, challenge constructively, build alignment, and influence outcomes without direct authority; deliver against broad objectives and competing priorities; plan and execute consistently; and approach problem solving systematically.
  • Occasional travel to Kite/Gilead locations may be required.
Responsibilities
  • Build trusted relationships with leaders and stakeholders across Supply Chain, Manufacturing, Logistics, Quality, and Patient Operations; understand their priorities and translate business needs into technology strategies, roadmaps, and executable solutions.
  • Lead cross-functional alignment across business, IT, vendors, and support organizations by facilitating decisions, clarifying priorities and trade-offs, and driving issues through resolution to achieve successful business outcomes.
  • Serve as the technical authority for Kite Konnect Enterprise and Supply Chain architecture, integrations, APIs, customizations, interfaces, and data management solutions, ensuring designs are scalable, supportable, reliable, and aligned with Gilead architecture standards.
  • Own the Kite Konnect Enterprise and Supply Chain IT business capability roadmap with business stakeholders, balancing operational needs, compliance requirements, technical modernization, and strategic growth initiatives.
  • Oversee Kite Konnect Enterprise and Supply Chain IT release planning, SDLC governance, environment management, deployment readiness, testing strategies, change management, patching, upgrades, and rollback procedures to ensure safe and effective system changes.
  • Own the health, stability, performance, and operational resilience of Kite Konnect Enterprise and Supply Chain platforms and integrations, including incident response, root cause analysis, corrective actions, service metrics, monitoring, and support governance.
  • Lead integration and data-related activities across Oracle EBS, SAP, Salesforce, and downstream applications, including reliability, error handling, interoperability, data quality, migration, reconciliation, and master data governance.
  • Provide direction to managed service providers, implementation partners, and support teams; manage priorities, backlog, resource planning, service delivery performance, SLAs, and partner accountability.
  • Communicate system health, risks, incidents, project status, recommendations, and operational trends to leadership, business partners, vendors, and cross-functional teams.
  • Lead a team of onshore and offshore functional and technical analysts; establish the support model and performance management with the system integration partner, manage resource allocations, define technical standards, and serve as the primary escalation point.
  • Serve as the local technical lead for critical incidents affecting patient treatment, supply chain logistics, chain of custody and identity, labeling support, and other time-sensitive operations.
Desired Qualifications
  • Significant relevant experience in a commercial life science, pharmaceutical, or similarly regulated environment.

About the company

G

Gilead Sciences

View
cbWebsite

Gilead Sciences is a biopharmaceutical company that discovers, develops and sells medicines for HIV, viral hepatitis and other liver diseases, cancer and inflammatory conditions. Its HIV business covers both treatment, led by the once-daily pill Biktarvy, and prevention, including Descovy and Yeztugo, a lenacapavir injection given twice a year. In cancer, its Kite unit makes CAR T-cell therapies from patients' own immune cells, and Trodelvy is an antibody-drug conjugate for breast cancer. Gilead earns revenue by selling its drugs to wholesalers, specialty pharmacies, hospitals and governments worldwide after regulatory approval. The company was founded in 1987 and is headquartered in Foster City, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead is expanding at headquarters: it broke ground on a Foster City biologics plant in August 2026.
  • Its top seller has a long runway: generic deals keep US copies of Biktarvy off shelves until April 2036.
  • Acquisitions add teams to join: Gilead bought German drug developer Tubulis for about $3.2 billion in May 2026.

What critics are saying

  • Sales lean on one disease: HIV drugs made $5.7 billion of Gilead's $7.8 billion revenue in Q2 2026.
  • Medicare will set Biktarvy's price: officials picked it in January 2026 for negotiated prices starting in 2028.
  • Expect cuts: Gilead reported 108 Redwood City and 51 San Mateo layoffs taking effect by June 2026.

What makes Gilead Sciences unique

  • Gilead sells a twice-a-year HIV prevention shot: Yeztugo replaces daily pills with two injections a year.
  • Gilead now fully owns a myeloma cell therapy: it bought partner Arcellx for about $7.8 billion in April 2026.
  • Gilead makes cell therapies in-house: Kite runs its own CAR T plants in California, Maryland and Amsterdam.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid family time off and paid parental time off
  • Generous 401(k) contribution matching
  • Comprehensive medical plans that cover both physical and mental healthcare
  • Global Wellbeing Reimbursement
  • Time Off
  • Global Volunteer Day
  • Giving Together Program
  • Employee Support Programs
  • Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
BioSpace
Oct 20th, 2026
Gilead's 'highly competitive' mid-stage ulcerative colitis data 'validate' I&I push.

Gilead's 'highly competitive' mid-stage ulcerative colitis data 'validate' I&I push. October 20, 2026 | Gilead's emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolstering the company's push beyond its HIV portfolio. Gilead Sciences' investigational drug emvistegrast delivered higher response rates versus placebo in a Phase 2 study of ulcerative colitis - findings that analysts at BMO Capital Markets say "validate" the pharma's efforts to diversify beyond HIV and into immunology and inflammation. "Gilead's asset looks highly competitive vs other a4b7 agents," BMO wrote in a note on Monday. The group pointed to Eli Lilly's zotemtegrast and Takeda's Entyvio, which similarly block the a4b7 integrin in order to suppress inflammation in the gut. In the mid-stage SWIFT trial, 238 patients with moderately to severely active ulcerative colitis were randomly assigned to receive 200 mg, 75 mg or 25 mg of oral emvistegrast daily or placebo. Results, presented Monday at the 2025 United European Gastroenterology Week in Barcelona, Spain, showed that 66% of patients on the highest dose of emvistegrast achieved clinical response, compared to 37% of patients on placebo. The treatment benefit was nominally significant, meeting the study's primary endpoint. Clinical response rates for the 75-mg and 25-mg doses of emvistegrast were 51% and 43%, respectively, according to Gilead's presentation at the conference. With these data, Gilead plans to take emvistegrast into late-stage development - a Phase 3 study set to start next year - with an eye toward future emvistegrast combination therapies, said Swati Tole, senior vice president of Clinical Development, Inflammation, in a prepared statement. Gilead is also looking to launch a Phase 2b/3 study of the asset in Crohn's disease, noted BMO, which also flagged the company's plans to test emvistegrast in combination with other assets, both internal and external, for inflammatory bowel disease. "Taken together, we view SWIFT as an incremental positive for Gilead's inflammatory strategy that establishes emvistegrast as a credible oral a4b7 option," the analysts wrote. Like BMO, analysts at Truist Securities "view the 200 mg cohort results as competitive," they told investors on Monday. However, the firm pointed out that "dose response is not perfect," particularly in terms of secondary endpoints. Rates of clinical remission, for instance, reached 31% in the highest dose group, but came out to 9% and 20% in the 75-mg and 25-mg arms, respectively. Remission in placebo was 8%. A similar pattern emerged for the other secondary endpoints - including mucosal healing, endoscopic improvement and histologic endoscopic mucosal improvement - with "75 mg underperforming 25 mg," Truist explained. Gilead chalked up the lack of a dose response effect to "potential study noise" and small treatment arm sizes, the analysts wrote after speaking with Tole and other members of the Gilead team. The pharma hasn't yet provided a mechanistic explanation for this discrepancy, Truist flagged. "Despite an uneven dose response, we see the data as encouraging clinical POC [proof of concept] for emvistegrast and another step in GILD's broader I&I ambitions," Truist noted. Indeed, Gilead's business is heavily reliant on its HIV portfolio, which in the second quarter accounted for $5.7 billion of the company's total $7.8 billion sales. Seeking to diversify, Gilead has recently struck multiple deals beyond its infectious disease comfort zone. In February, for instance, the pharma dropped $7.8 billion to swallow its CAR T collaborator Arcellx ahead of a key decision for the partners' investigational multiple myeloma therapy anitocabtagene autoleucel (anito-cel). The asset is under review with a decision expected by Dec. 23. Other pickups in Gilead's diversification drive this year include the inflammatory biotech Ouro Medicines and the antibody-drug conjugate (ADC) developer Tubulis, with which the bigger company had previously partnered and which will operate as an ADC specialist under the Gilead umbrella. Gilead last week also secured an equity stake in Vir Biotechnology, giving its vote of confidence to the biotech's T cell engager platform. The pharma put up to $1.74 billion on the line in milestones, and in return received three dual-masked T cell engagers that it plans to study for solid tumors. HIV remained Gilead's strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology. August 5, 2026

Financial News
Oct 19th, 2026
Gilead's UC pill hits trial goal, stock still slips.

Gilead's UC pill hits trial goal, stock still slips. Gilead Sciences (NASDAQ: GILD) said on 19 October 2026 that its experimental ulcerative colitis pill met the main goal of a mid-stage trial. The Gilead ulcerative colitis trial, known as SWIFT, tested emvistegrast, an oral once-daily treatment, in adults with moderately to severely active disease. At the 200mg dose, 66% of patients achieved a clinical response at Week 12 under the modified Mayo score, against 37% on placebo, according to PharmaShots. Clinical remission was reached by 31% of patients on the drug, compared with 8% on placebo, Reuters reported. Trial data presented at European gastroenterology meeting. Gilead unveiled the late-breaking Phase 2 findings at United European Gastroenterology Week 2026. The company said its experimental once-daily pill reduced symptoms of the chronic bowel illness in more patients than placebo, meeting the trial's main goal, as Reuters reported. Emvistegrast, also known as GS-1427, is a selective oral alpha4beta7 integrin inhibitor. Gilead is positioning the pill against injectable biologics such as vedolizumab and oral rivals including Abivax's obefazimod in a crowded inflammatory bowel disease field. The drug showed a generally well-tolerated safety profile during the induction phase, Benzinga reported. Shares fall despite the positive readout. GILD shares closed at $153.555 on 19 October, down 1.42% on the day. Trading volume ran at 0.82 times the 20-day average, suggesting limited conviction behind the move. RBC Capital Markets had told clients the emvistegrast readout was unlikely to move the stock, according to MarketScreener. The muted reaction underlines that Street positioning, rather than the trial's raw numbers, set the terms of the share response. FINRA short-volume data for GILD in the fortnight before the announcement showed the daily short ratio moving between roughly 0.37 and 0.57, with no sustained build-up that would point to advance positioning against the news. Earnings swing colours the backdrop. The trial news lands against a volatile run of quarterly results. Gilead posted a net loss of $10,496m, or diluted earnings per share of -$8.45, for the second quarter of 2026, a sharp reversal from net income of $2,021m and EPS of $1.61 in the first quarter, according to the company's 10-Q filing with the SEC. Revenue for the second quarter came in at $7,803m, up from $6,960m in the first three months of the year, filings show. The swing follows a pattern of uneven quarters stretching back through 2024 and 2025. Gilead reported a net loss of $4,170m in the first quarter of 2024 before returning to profit of $1,614m in the second quarter that year, and has posted net income in every quarter since bar the latest one, according to EDGAR records. Quarterly revenue has climbed steadily over the period, from $6,686m in the first quarter of 2024 to $7,803m two years later. Two Gilead insiders, Andrew D. Dickinson and Johanna Mercier, filed Form 4 disclosures with the SEC on 16 October 2026, three days before the trial announcement, according to EDGAR records. The filings do not themselves indicate the direction or scale of any transactions tied to the disclosures. Macro backdrop stays mixed for pharma stocks. The readout also arrives as broader market conditions stay unsettled for healthcare names reliant on long-dated pipeline bets. The 10-year US Treasury yield stood at 5.1% as of 15 October 2026, down slightly from 5.19% a month earlier, according to Federal Reserve data. The 2-year yield sat at 4.77%, leaving the 10-year/2-year spread at 0.35 percentage points, little changed from 0.33 points previously. US consumer prices rose to an index level of 336.298 in September, up from 334.131 the prior month, Federal Reserve data show, while the unemployment rate ticked up to 4.2% from 4.1%. None of that macro data bears directly on Gilead's trial outcome, but it frames a backdrop in which investors have shown little appetite to reward clinical headlines that fall short of outright surprise. Gilead has not disclosed a timeline for advancing emvistegrast into late-stage testing. Investors will watch for further detail at the company's next quarterly results and for any read-across from rival oral IBD programmes now in development. This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.

Investing.com
Oct 19th, 2026
Gilead to present HIV and antiviral research at IDWeek 2026.

Gilead to present HIV and antiviral research at IDWeek 2026. Published Oct 19, 2026, 08:12 AM (C) Reuters FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) announced it will present 28 research findings at IDWeek 2026, scheduled for October 21-24 in Washington, D.C., according to a press release statement. The presentations will include data on Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), the company's once-daily single tablet regimen for HIV treatment in virologically suppressed adults. New analyses from the Phase 3 ARTISTRY-1 and ARTISTRY-2 studies will examine treatment outcomes in participants with comorbidities including dyslipidemia, hypertension, diabetes mellitus and renal impairment. The company will present real-world data on early U.S. adoption of Yeztugo (lenacapavir) for HIV pre-exposure prophylaxis during the first nine months following FDA approval. The oral presentation will cover adoption patterns from June 2025 through March 2026. Yeztugo is administered twice-yearly. Additional research will include final Phase 1b results for investigational GS-1179, an oral herpes simplex virus helicase-primase inhibitor being developed for suppression of recurrent genital herpes. The presentations will cover virologic efficacy, safety and tolerability data. Other studies will examine factors influencing HIV prevention access, antiretroviral therapy restart strategies, and treatment patterns in real-world settings. Data from the Phase 4 ACCELERATE Implementation Study will examine rapid antiretroviral therapy restart for people with HIV returning to care using Biktarvy. Bixlenvo is approved in the U.S. for HIV treatment but not approved outside the U.S. Yeztugo is approved in the U.S., EU, Canada, Brazil, South Africa, Australia, Zambia and Zimbabwe for HIV prevention. GS-1179 remains investigational. Included in its AI-picked strategies -1.38 (-0.88%) Real-time Data · 13:43:21 · USD Start trading GILD now Should you invest $2,000 in GILD right now? ProPicks AI evaluates GILD alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if GILD is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

Transcript Daily
Oct 18th, 2026
Gilead Sciences, Inc. $GILD stake cut by TD Waterhouse Canada Inc.

Gilead Sciences, Inc. $GILD stake cut by TD Waterhouse Canada Inc. TD Waterhouse Canada Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 68.1% during the third quarter, according to its most recent filing with the SEC. The firm owned 153,802 shares of the biopharmaceutical company's stock after selling 328,399 shares during the period. TD Waterhouse Canada Inc.'s holdings in Gilead Sciences were worth $22,698,000 at the end of the most recent reporting period. A number of other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. Legal & General Group Plc bought a new position in shares of Gilead Sciences in the 2nd quarter worth $1,316,606,000. Deutsche Bank AG bought a new position in shares of Gilead Sciences in the 2nd quarter worth $918,387,000. Jupiter Topco LLC purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth $398,905,000. Hedge funds and other institutional investors own 83.67% of the company's stock. Gilead Sciences news roundup. Here are the key news stories impacting Gilead Sciences this week: * Vir oncology collaboration expands Gilead's pipeline. Gilead and Vir Biotechnology agreed to develop three novel cancer therapies, including next-generation T-cell engagers. The deal could provide Vir with up to approximately $1.74 billion in additional milestone payments, giving Gilead access to potential long-term oncology growth while diversifying its pipeline. * Investors are rotating toward defensive healthcare stocks. As investors reduce exposure to technology and chip stocks, major pharmaceutical companies - including Gilead - have traded near record highs. This rotation may be supporting demand for GILD because of the sector's defensive characteristics and potential earnings support. * Recent momentum has increased investor attention. GILD gained 2.57% in the prior session and closed at $157.48, while shares remain close to their 52-week high. Market commentary notes heightened investor interest, although analysts have expressed mixed views on the company's prospects. * Two senior executives reported planned stock sales. CFO Andrew Dickinson and insider Johanna Mercier each sold 3,000 shares at an average price of $156.22. Both transactions were executed under pre-arranged Rule 10b5-1 plans, limiting their significance as a bearish signal; each executive continues to hold a substantial position. Analyst upgrades and downgrades. A number of equities research analysts recently weighed in on GILD shares. Truist Financial raised their price objective on Gilead Sciences from $150.00 to $158.00 and gave the company a "buy" rating in a research report on Wednesday, October 7th. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $123.00 to $126.00 and gave the stock a "sector perform" rating in a report on Thursday, October 8th. Barclays reduced their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a report on Wednesday, July 29th. Wall Street Zen raised shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research report on Saturday, September 19th. Finally, Leerink Partners cut shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $159.33. Gilead Sciences price performance. NASDAQ GILD opened at $156.19 on Friday. The firm's fifty day simple moving average is $147.19 and its two-hundred day simple moving average is $137.29. The firm has a market capitalization of $193.67 billion, a P/E ratio of -58.50 and a beta of 0.31. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 12-month low of $114.02 and a 12-month high of $160.51. Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The business had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the prior year, the firm posted $2.01 earnings per share. The business's quarterly revenue was up 10.6% on a year-over-year basis. Analysts forecast that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year. Gilead Sciences announces dividend. The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.1%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences's payout ratio is -122.85%. Insider activity. In related news, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director directly owned 10,066 shares of the company's stock, valued at $1,459,771.32. This represents a 33.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the sale, the chief financial officer owned 161,096 shares of the company's stock, valued at approximately $25,166,417.12. This trade represents a 1.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 111,000 shares of company stock worth $15,877,860 over the last quarter. Company insiders own 0.30% of the company's stock. Gilead Sciences profile. Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19. Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary. Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report). Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

TradingView
Oct 16th, 2026
Stocktwits biotech dealmaker: Gilead, AstraZeneca and Roche chase pipeline expansion over buyouts.

Stocktwits biotech dealmaker: Gilead, AstraZeneca and Roche chase pipeline expansion over buyouts. Key points: * Gilead Sciences partnered with Vir Biotechnology on Wednesday to discover and develop three drugs aimed at solid tumors. * AstraZeneca signed an up-to-$1.5 billion AI collaboration with insitro for MASH and cardiomyopathies. * Roche licensed Rona's drug candidate, and Zealand Pharma teamed with Generate on AI-designed proteins for differentiated obesity approaches. Large pharmaceutical companies including Gilead Sciences, Roche and AstraZeneca spent this week securing access to discovery technologies and experimental candidates that address clear biological gaps, instead of large-scale acquisitions of rival firms or approved products. Obesity and cancer remained the clear focal points, with several of the week's biggest partnerships aimed at differentiated weight-loss mechanisms or new solid-tumor approaches. Gilead Partners With Vir For New Cancer Drug Candidates Gilead Sciences (GILD) partnered with Vir Biotechnology (VIR) on Wednesday to discover and develop three drugs aimed at solid tumors. Vir will handle early discovery, design, and optimization using its AI-enabled protein engineering tools and PRO-XTEN masking technology. Gilead receives exclusive rights to nominate candidates and will lead subsequent development, manufacturing, and commercialization. Vir is eligible for $90 million upfront - $65 million in cash plus a $25 million equity investment at a premium - plus up to $45 million in near-term preclinical milestones and as much as $1.74 billion in later development, regulatory, and commercial payments, along with tiered royalties. The agreement marks Vir's second major partnership around its masking platform this year after a previous deal with Astellas and adds to Gilead's attempts to advance its cancer offerings besides its blockbuster drug Trodelvy. AstraZeneca Taps Insitro's AI Platform AstraZeneca (AZN) signed a worldwide exclusive research collaboration with privately held AI therapeutics company insitro focused on metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Insitro will apply its Virtual Human platform, which combines human and cellular data with AI, to identify causal disease biology and advance AstraZeneca-nominated targets through discovery to the development-candidate stage. AstraZeneca will lead clinical development, regulatory work, and commercialization. Insitro will receive $40 million upfront and is eligible for up to approximately $1.46 billion in discovery, development, and commercial milestones, plus single-digit royalties on potential sales. Roche, Zealand Pharma Add Differentiated Obesity Approaches Roche secured exclusive worldwide rights to Rona Therapeutics' investigational drug candidate which targets a protein predominantly expressed in fat tissues. The drug candidate is designed to selectively reduce visceral and ectopic fat while preserving lean mass - an attractive complement to currently popular obesity drug classes like GLP-1. Rona is eligible for up to $100 million in upfront and near-term payments, up to $1.06 billion in additional milestones, and tiered royalties. Separately, Zealand Pharma entered a collaboration with Generate Biomedicines (GENB) to design multispecific protein therapeutics for obesity and other metabolic diseases using Generate's generative AI platform. Generate will lead research through lead-candidate selection for two initial programs, with an option for a third; Zealand will handle clinical development, regulatory submissions, and commercialization. Generate receives $30 million upfront, up to $35 million in early preclinical milestones, and nearly $1.2 billion in total potential milestones, plus royalties. Pfizer, Galderma Make Platform And Commercial Moves Pfizer (PFE) partnered with privately-held Enodia Therapeutics on a research collaboration and license for compounds intended to block disease-driving proteins at the point of synthesis. The potential value exceeds $500 million, including an upfront payment, milestones, and royalties; Enodia will run discovery against multiple targets while Pfizer takes over later development and commercialization. How Did Retail Traders React? On Stocktwits, retail sentiment around SPDR S&P Biotech ETF (XBI) fell from bullish to neutral territory over the past 24 hours, while message volume stayed at normal levels. XBI has fallen 4% over the past week as part of a broader biotech pullback that began after its mid-August peak near $170, but it is up 22.5% year-to-date.